Alzheimer's Drug Shows Some Success (LLY, PFE, ELN)

Drugmaker Eli Lilly & Co. (NYSE: LLY) announced this morning that the company's solanezumab treatment for Alzheimer's disease failed to meet both the cognitive and functional endpoints in recently completed phase 3 double-blind trials. The Eli Lilly trials did yield some success though:

[A] pre-specified secondary analysis of pooled data across both trials showed statistically significant slowing of cognitive decline in the overall study population of patients with mild-to-moderate Alzheimer's disease. In addition, pre-specified secondary subgroup analyses of pooled data across both studies showed a statistically significant slowing of cognitive decline in patients with mild Alzheimer's disease, but not in patients with moderate Alzheimer's disease.

About a month ago, rivals Pfizer Inc. (NYSE: PFE) and Elan Corp. PLC (NYSE: ELN) said that their jointly developed Alzheimer's treatment, bapineuzumab, had failed late-stage trials.

The company's CEO/chairman/president said:

We recognize that the solanezumab studies did not meet their primary endpoints, but we are encouraged by the pooled data that appear to show a slowing of cognitive decline. We intend to discuss these data with regulatory authorities to gain their insights on potential next steps.

Eli Lilly's shares are up about 5% in premarket trading this morning, at $44.50 in a 52-week range of $34.94 to $44.67.

Paul Ausick


Filed under: 24/7 Wall St. Wire, Drug companies, Pharmaceuticals, Regulation Tagged: ELN, LLY, PFE
Read Full Story

Markets

DJIA 25,090.48 -84.83 -0.34%
NASDAQ 7,746.38 -14.66 -0.19%
NIKKEI 225 22,772.52 -79.23 -0.35%
HANG SENG 30,309.49 -130.68 -0.43%
DAX 13,010.55 -96.55 -0.74%
USD (per EUR) 1.16 0.00 -0.07%
USD (per CHF) 1.00 0.00 0.03%
JPY (per USD) 110.48 -0.13 -0.12%
GBP (per USD) 1.33 0.00 -0.04%